Drugs / FDA022-BB05
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05564858 | Jan 2023 → Sep 2025 | cancer | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06413615 | May 2024 → Jul 2025 | neoplasm | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FDA022-BB05 | “FDA022-BB05 is administered via intravenous infusion using an accelerated titration method followed by a conventional 3 + 3 study design to identify dose-limiting...” NCT05564858 ↗ |
| Modality | Monoclonal antibody | “FDA022 Monoclonal antibody-drug conjugate for injection Phase Ia” NCT05564858 ↗ |
| Route | Intravenous | “FDA022-BB05, intravenously infusion, q3w” NCT05564858 ↗ |